Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.
An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-mediated immune (CMI) responses against divergent HIV-1 clades. We compared anti-HIV-1 T-cell immune responses among 363 unvaccinated adults infected with diverse HIV-1 clades. Response rates to clade B Gag and/or clade B Nef in Botswana (95%) and Cameroon (98%) were similar when compared with those in countries previously studied, including Brazil (92%), Thailand (96%), South Africa (96%), Malawi (100%), and the United States (100%). Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples.
Gupta
Swati B
SB
Merck and Co., Inc., Whitehouse Station, NJ, USA. swati_gupta@merck.com
Mast
Christopher T
CT
Wolfe
Nathan D
ND
Novitsky
Vlad
V
Dubey
Sheri A
SA
Kallas
Esper G
EG
Schechter
Mauro
M
Mbewe
Bernard
B
Vardas
Eftyhia
E
Pitisuttithum
Punee
P
Burke
Donald
D
Freed
Dan
D
Mogg
Robin
R
Coplan
Paul M
PM
Condra
Jon H
JH
Long
Romnie S
RS
Anderson
Kiersten
K
Casimiro
Danilo R
DR
Shiver
John W
JW
Straus
Walter L
WL
D000293:Adolescent; D000328:Adult; D001902:Botswana; D002163:Cameroon; D002478:Cells, Cultured; D005260:Female; D015683:Gene Products, gag / Q000276:immunology; D015693:Gene Products, nef / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008875:Middle Aged; D037182:T-Cell Antigen Receptor Specificity; D013601:T-Lymphocytes / Q000276:immunology*; D054311:nef Gene Products, Human Immunodeficiency Virus
D015683:Gene Products, gag; D015693:Gene Products, nef; D015488:HIV Antigens; D054311:nef Gene Products, Human Immunodeficiency Virus; D007371:Interferon-gamma